Literature DB >> 17465455

Genetic variability of CYP2B6 polymorphisms in four southern Chinese populations.

Bing-Ying Xu1, Li-Ping Guo, Shui-Shan Lee, Qing-Ming Dong, Yi Tan, Hong Yao, Li-Hua Li, Che-Kit Lin, Hsiang-Fu Kung, Ming-Liang He.   

Abstract

AIM: To investigate the genotype and allelic frequencies of Cytochrome P450 2B6 polymorphisms in four southern Chinese populations.
METHODS: DNA was obtained from blood samples from Han Chinese from Hong Kong and three minority groups, the Wa, Bulang and Lahu from Yunnan in southern China. Genotyping was performed using real-time PCR and confirmed by direct sequencing.
RESULTS: A total of 507 subjects from southern China were studied. Results showed there is a high prevalence of 516G > T (34.5%) in ethnic Chinese compared to literature reports on other Asian populations and Caucasians. The frequency of the 516TT genotype is higher in the Han majority (23.1%) than in three other ethnic minority groups (i.e., 7.4%, 9.1% and 15.8%) in southern China.
CONCLUSION: This was the first study to document the spectrum of CYP2B6 allelic variants and genotypes in a southern Chinese population. The 516G > T allele is associated with a defective metabolism of efavirenz (EFV), which therefore may predispose to drug toxicity. Treatment regimens for human immunodeficiency virus (HIV) and heroin addiction may need to be optimized in different populations because of the marked variability of the key metabolizing enzyme.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465455      PMCID: PMC4319132          DOI: 10.3748/wjg.v13.i14.2100

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  16 in total

1.  A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by autoactivation.

Authors:  N Ariyoshi; M Miyazaki; K Toide; T Kamataki
Journal:  Biochem Biophys Res Commun       Date:  2001-03       Impact factor: 3.575

2.  Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study.

Authors:  David W Haas; Heather J Ribaudo; Richard B Kim; Camlin Tierney; Grant R Wilkinson; Roy M Gulick; David B Clifford; Todd Hulgan; Catia Marzolini; Edward P Acosta
Journal:  AIDS       Date:  2004-12-03       Impact factor: 4.177

3.  Influence of 516G>T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects.

Authors:  Sonia Rodriguez-Novoa; Pablo Barreiro; Ana Rendón; Inmaculada Jiménez-Nacher; Juan González-Lahoz; Vincent Soriano
Journal:  Clin Infect Dis       Date:  2005-03-31       Impact factor: 9.079

4.  The implications of a high allelic frequency of CYP2B6 G516T in ethnic Chinese persons.

Authors:  Kenneth Tong; Ming-Liang He; Che-Kit Lin; Liping Guo; Hsiang-Fu Kung; Joseph J Y Sung; Shui-Shan Lee
Journal:  Clin Infect Dis       Date:  2006-08-15       Impact factor: 9.079

5.  Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population.

Authors:  Masahiro Hiratsuka; Yoh Takekuma; Naomi Endo; Kaori Narahara; Samar Ismail Hamdy; Yukinaga Kishikawa; Masaki Matsuura; Yasuyuki Agatsuma; Tomoko Inoue; Michinao Mizugaki
Journal:  Eur J Clin Pharmacol       Date:  2002-08-14       Impact factor: 2.953

6.  Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese.

Authors:  Su Guan; Min Huang; Eli Chan; Xiao Chen; Wei Duan; Shu-Feng Zhou
Journal:  Eur J Pharm Sci       Date:  2006-05-02       Impact factor: 4.384

7.  Pharmacogenetics of long-term responses to antiretroviral regimens containing Efavirenz and/or Nelfinavir: an Adult Aids Clinical Trials Group Study.

Authors:  David W Haas; Laura M Smeaton; Robert W Shafer; Gregory K Robbins; Gene D Morse; Line Labbe; Grant R Wilkinson; David B Clifford; Richard T D'Aquila; Victor De Gruttola; Richard B Pollard; Thomas C Merigan; Martin S Hirsch; Alfred L George; John P Donahue; Richard B Kim
Journal:  J Infect Dis       Date:  2005-11-01       Impact factor: 5.226

8.  Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6.

Authors:  Julia Kirchheiner; Christian Klein; Ingolf Meineke; Johanna Sasse; Ulrich M Zanger; Thomas E Mürdter; Ivar Roots; Jürgen Brockmöller
Journal:  Pharmacogenetics       Date:  2003-10

Review 9.  The expression of CYP2B6, CYP2C9 and CYP3A4 genes: a tangle of networks of nuclear and steroid receptors.

Authors:  J M Pascussi; S Gerbal-Chaloin; L Drocourt; P Maurel; M J Vilarem
Journal:  Biochim Biophys Acta       Date:  2003-02-17

10.  Identification of CYP2B6 sequence variants by use of multiplex PCR with allele-specific genotyping.

Authors:  Robyn M Jacob; Elaine C Johnstone; Matt J Neville; Robert T Walton
Journal:  Clin Chem       Date:  2004-06-03       Impact factor: 8.327

View more
  14 in total

1.  Impact of Single Nucleotide Polymorphisms on Plasma Concentrations of Efavirenz and Lopinavir/Ritonavir in Chinese Children Infected with the Human Immunodeficiency Virus.

Authors:  Xia Liu; Qing Ma; Yan Zhao; Weiwei Mu; Xin Sun; Yuewu Cheng; Huiping Zhang; Ye Ma; Fujie Zhang
Journal:  Pharmacotherapy       Date:  2017-09-03       Impact factor: 4.705

2.  Ethnic-specific in vitro-in vivo extrapolation and physiologically based pharmacokinetic approaches to predict cytochrome P450-mediated pharmacokinetics in the Chinese population: opportunities and challenges.

Authors:  Guo-Fu Li; Guo Yu; Hong-Xia Liu; Qing-Shan Zheng
Journal:  Clin Pharmacokinet       Date:  2014-02       Impact factor: 6.447

3.  Expression of P450 and nuclear receptors in normal and end-stage Chinese livers.

Authors:  Hong Chen; Zhong-Yang Shen; Wang Xu; Tie-Yan Fan; Jun Li; Yuan-Fu Lu; Ming-Liang Cheng; Jie Liu
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

4.  Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment.

Authors:  Jing Li; Vincent Menard; Rebekah L Benish; Richard J Jurevic; Chantal Guillemette; Mark Stoneking; Peter A Zimmerman; Rajeev K Mehlotra
Journal:  Pharmacogenomics       Date:  2012-04       Impact factor: 2.533

Review 5.  The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long-Term ARV Treatment.

Authors:  Mei Tan; Megan Bowers; Phil Thuma; Elena L Grigorenko
Journal:  New Dir Child Adolesc Dev       Date:  2020-07-12

Review 6.  Neurological and psychiatric adverse effects of antiretroviral drugs.

Authors:  Michael S Abers; Wayne X Shandera; Joseph S Kass
Journal:  CNS Drugs       Date:  2014-02       Impact factor: 5.749

7.  Influence of CYP2B6 polymorphisms on the persistence of plasma nevirapine concentrations following a single intra-partum dose for the prevention of mother to child transmission in HIV-infected Thai women.

Authors:  Soranun Chantarangsu; Tim R Cressey; Surakameth Mahasirimongkol; Edmund Capparelli; Yardpiroon Tawon; Nicole Ngo-Giang-Huong; Gonzague Jourdain; Marc Lallemant; Wasun Chantratita
Journal:  J Antimicrob Chemother       Date:  2009-10-06       Impact factor: 5.790

8.  Pharmacogenomics of CYP2A6, CYP2B6, CYP2C19, CYP2D6, CYP3A4, CYP3A5 and MDR1 in Vietnam.

Authors:  M I Veiga; S Asimus; P E Ferreira; J P Martins; I Cavaco; V Ribeiro; T N Hai; M G Petzold; A Björkman; M Ashton; J P Gil
Journal:  Eur J Clin Pharmacol       Date:  2008-11-01       Impact factor: 2.953

9.  Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.

Authors:  Xianmin Meng; Kang Yin; Jiangrong Wang; Ping Dong; Li Liu; Yinzhong Shen; Li Shen; Qing Ma; Hongzhou Lu; Weimin Cai
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

10.  Dose Optimization of Efavirenz Based on Individual CYP2B6 Polymorphisms in Chinese Patients Positive for HIV.

Authors:  K H Hui; S S Lee; T N Lam
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-04-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.